Glycaemic outcomes were equally striking: 7782% of participants on retatrutide achieved euglycaemia (HbA1c 6.5%), and between 5763% achieved body weight reductions of 15% or more
Adverse event-related discontinuation rates were 8% among liraglutide-treated patients compared to 4% of placebo recipients [44]
This is the same physiologic process seen when someone stops lifting weights: muscle size decreases because the stimulus is gonenot because muscle is being destroyed. Common Misconception: GLP-1 Drugs Burn Muscle Reality: Muscle loss during GLP-1associated weight loss is driven by reduced mechanical load and insufficient protein/calories , not by a toxic or catabolic drug effect. When Lean-Mass Loss Becomes True Muscle Wasting True muscle wasting is uncommon with GLP-1 therapy and is usually related to undernutrition , not the medication itself
"Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review"
Thigh lift procedures can improve contour along the inner or outer thighs
Medication access: About 67.1% of the cohort accessed only one GLP-1, while 25.9% accessed two distinct GLP-1 medications, and 7% accessed three or more
